Updates in CLL from EHA 2024: combinations of BTK and BCL2 inhibitors, BTK degraders, and more

  Рет қаралды 516

VJHemOnc – Video Journal of Hematology & HemOnc

VJHemOnc – Video Journal of Hematology & HemOnc

Күн бұрын

Toby Eyre, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), MD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, and Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, discuss updates to the treatment of chronic lymphocytic leukemia (CLL) and Richter's transformation (RT) from the 2024 EHA meeting. They focus on combinations of BTK and BCL2 inhibitors, the efficacy of BTK degraders in CLL, and the role of epcoritamab in the treatment of RT. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Пікірлер
Это было очень близко...
00:10
Аришнев
Рет қаралды 6 МЛН
НИКИТА ПОДСТАВИЛ ДЖОНИ 😡
01:00
HOOOTDOGS
Рет қаралды 3 МЛН
How I Turned a Lolipop Into A New One 🤯🍭
00:19
Wian
Рет қаралды 13 МЛН
Сюрприз для Златы на день рождения
00:10
Victoria Portfolio
Рет қаралды 2,7 МЛН
New Treatment Guidelines to Chronic Lymphocytic Leukemia (CLL): Latest advances & treatments
1:01:37
The Leukemia & Lymphoma Society of Canada
Рет қаралды 5 М.
The Truth About Managing CLL Treatment Side Effects
5:20
Patient Empowerment Network
Рет қаралды 123
Managing CLL Symptoms and Treatment Side Effects
4:14
Patient Empowerment Network
Рет қаралды 222
2024 CLL/SLL Survey  - key findings and discussion
18:18
CLL Support Association (CLLSA)
Рет қаралды 236
What is new in ITP? Prof. David Kuter
20:03
ITP Support Association
Рет қаралды 1,1 М.
Это было очень близко...
00:10
Аришнев
Рет қаралды 6 МЛН